Showing results (91-100 of 331) with videos related to
Sort By:
Pageof 34
BMC Cancer|September 20, 2022
Immune checkpoint inhibitors and their impact on liver enzymes and attenuationBenjamin C Park, Aaron X T Lee, Fei Ye, et al.American Journal of Clinical Dermatology|June 16, 2022
Challenging Dermatologic Considerations Associated with Immune Checkpoint InhibitorsBenjamin C Park, Seungyeon Jung, Steven T Chen, et al.The Oncologist|August 5, 2023
Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint InhibitorsRobert N Grad, Seungyeon Jung, Fei Ye, et al.Clinical Lung Cancer|February 25, 2023
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung CancerWade T Iams, Meridith L Balbach, Sharon Phillips, et al.Journal of the American Academy of Dermatology|August 1, 2021
Cutaneous adverse events caused by immune checkpoint inhibitorsHenry T Quach, Douglas B Johnson, Nicole R LeBoeuf, et al.Oncoimmunology|December 22, 2016
Responses to immune checkpoint inhibitors in nonagenariansRomany A N Johnpulle, Robert M Conry, Jeffrey A Sosman, et al.Frontiers in Oncology|October 20, 2025
Evaluating the impact of immune checkpoint inhibitors on liver steatosis and function: a retrospective cohort analysisSophie K Schellhammer, Jessica Quintos Day, Run Fan, et al.Oncotarget|December 25, 2014
Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approachWei Jiang, Peilin Jia, Katherine E Hutchinson, et al.The Oncologist|July 5, 2022
Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric OncologyKhalil Choucair, Abdul Rafeh Naqash, Caroline A Nebhan, et al.Current Cardiology Reports|February 22, 2017
Cardiovascular Toxicities Associated with Cancer ImmunotherapiesDaniel Y Wang, Gosife Donald Okoye, Thomas G Neilan, et al.Pageof 34